Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Vertex Pharmaceutic (VRTX)

Vertex Pharmaceutic (VRTX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 56,642,432
  • Shares Outstanding, K 257,150
  • Annual Sales, $ 3,048 M
  • Annual Income, $ 2,097 M
  • 60-Month Beta 1.49
  • Price/Sales 18.51
  • Price/Cash Flow 69.54
  • Price/Book 10.74

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 18 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.95
  • Number of Estimates 7
  • High Estimate 1.07
  • Low Estimate 0.79
  • Prior Year 1.00
  • Growth Rate Est. (year over year) -5.00%

Price Performance

See More
Period Period Low Period High Performance
1-Month
201.84 +8.88%
on 11/12/19
225.66 -2.62%
on 12/09/19
+17.86 (+8.84%)
since 11/11/19
3-Month
165.23 +33.00%
on 10/02/19
225.66 -2.62%
on 12/09/19
+46.65 (+26.95%)
since 09/11/19
52-Week
151.80 +44.77%
on 12/24/18
225.66 -2.62%
on 12/09/19
+46.53 (+26.86%)
since 12/11/18

Most Recent Stories

More News
Vertex's Kalydeco Gets EU Approval to Treat CF in Infants

Vertex's (VRTX) Kalydeco gains EU nod for use in infants with cystic fibrosis aged from six to less than 12 months with at least one of specified nine mutations in the CFTR gene.

ABBV : 86.70 (+0.16%)
ANIK : 54.25 (-2.11%)
PRQR : 8.77 (-3.52%)
VRTX : 220.00 (-0.12%)
Looking for a Growth Stock? 3 Reasons Why Vertex (VRTX) is a Solid Choice

Vertex (VRTX) possesses solid growth attributes, which could help it handily outperform the market.

VRTX : 220.00 (-0.12%)
Biotech Stock Roundup: ASH Data in Focus, Amgen Gets FDA Nod to Remicade Biosimilar

The biotech sector witnesses pipeline updates from the annual ASH meet.

GILD : 67.78 (+1.04%)
AMGN : 234.01 (+0.07%)
BLUE : 86.97 (+1.49%)
FATE : 18.67 (-1.27%)
VRTX : 220.00 (-0.12%)
REGN : 373.53 (+1.59%)
SAGE : 68.67 (+8.50%)
The Zacks Analyst Blog Highlights: Spark Energy, Vertex, ResMed, Prologis and Boston Beer

The Zacks Analyst Blog Highlights: Spark Energy, Vertex, ResMed, Prologis and Boston Beer

SPKE : 10.61 (+0.57%)
SAM : 376.91 (+1.33%)
RMD : 150.48 (+1.01%)
VRTX : 220.00 (-0.12%)
PLD : 89.80 (-1.47%)
NobleCon Investor Conference: Country Star Eric Paslay Joins Type 1 Diabetes Panel Presentation Entitled "A Functional Cure Could Be Imminent"

via NetworkWire -- Noble Capital Markets, Inc. ("Noble") announced today that country star Eric Paslay (with hits like "Friday Night") will join leading experts to offer a patient perspective on the Type...

NVO : 56.86 (-0.14%)
VRTX : 220.00 (-0.12%)
5 Defensive Stocks to Buy as Volatility Index Soars

On Dec 9, the fear gauge jumped 16% as uncertainties in the closure of U.S.-China trade deal instilled fear in investors. Here are five defensive stocks to shield your portfolio.

SPKE : 10.61 (+0.57%)
SAM : 376.91 (+1.33%)
RMD : 150.48 (+1.01%)
VRTX : 220.00 (-0.12%)
PLD : 89.80 (-1.47%)
Vertex Announces European Commission Approval for KALYDECO(R) (ivacaftor) in Infants With Cystic Fibrosis Ages 6 Months to Less Than 12 Months With Certain Mutations in the CFTR Gene

Vertex Pharmaceuticals (Europe) Limited today announced that the European Commission has granted approval of the label extension for KALYDECO(R) (ivacaftor) to include the treatment of infants with cystic...

VRTX : 220.00 (-0.12%)
Watch for Vertex Pharm to Potentially Pullback After Gaining 1.02% Yesterday

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $222.99 to a high of $225.66. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of...

VRTX : 220.00 (-0.12%)
Vertex Pharm Rises 1.02% on Heavy Volume: Watch For Potential Pullback

Vertex Pharm (NASDAQ:VRTX) traded in a range yesterday that spanned from a low of $222.99 to a high of $225.66. Yesterday, the shares gained 1.0%, which took the trading range above the 3-day high of...

VRTX : 220.00 (-0.12%)
Blueprint's (BPMC) Systemic Mastocytosis Study Data Impresses

Blueprint Medicines (BPMC) posts favorable initial data from the part 1 of phase II PIONEER study on avapritinib for the treatment of patients with indolent systemic mastocytosis. Stock rises.

BAYRY : 19.2300 (+0.52%)
RHHBY : 38.4900 (+0.23%)
BPMC : 72.80 (+2.41%)
VRTX : 220.00 (-0.12%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Trade VRTX with:

Business Summary

Vertex Pharmaceuticals Incorporated is a global biotechnology company that invests in scientific innovation to create transformative medicines for people with serious and life-threatening diseases. In addition to clinical development programs in CF, Vertex has more than a dozen ongoing research programs...

See More

Key Turning Points

2nd Resistance Point 223.58
1st Resistance Point 221.93
Last Price 220.00
1st Support Level 218.56
2nd Support Level 216.84

See More

52-Week High 225.66
Last Price 220.00
Fibonacci 61.8% 197.45
Fibonacci 50% 188.73
Fibonacci 38.2% 180.01
52-Week Low 151.80

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar